BITRF (Biotron) Treasury Stock: $0.00 Mil (As of Dec. 2025)


What is Biotron Treasury Stock?

Biotron BITRF Treasury Stock is $0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Biotron's treasury stock for the quarter that ended in Dec. 2025 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Biotron Treasury Stock Historical Data

* Premium members only.

The historical data trend for Biotron's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotron Treasury Stock Chart

Biotron Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biotron Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biotron Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $0.00 Mil mean?
Biotron (BITRF) has a Treasury Stock of $0.00 Mil as of Dec. 2025. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Biotron and its competitors.
Is Biotron's Treasury Stock too high?
Biotron's current Treasury Stock is $0.00 Mil.
How does Biotron's Treasury Stock compare to VRTX and REGN?
Biotron's Treasury Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Biotron and its competitors. Biotron's current Treasury Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotron stock overvalued right now?
Biotron (BITRF) has a current Treasury Stock of $0.00 Mil. The current Treasury Stock is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Biotron (BITRF), the current Treasury Stock is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotron Business Description

Other Exchanges BIT:Australia
Address 66 Hunter Street, Level 2, Sydney, NSW, AUS, 2000
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.